Tango Therapeutics/$TNGX
1D1W1MYTD1Y5YMAX
Capital at risk
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
- Ticker
- $TNGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 137
- Headquarters
- Boston, United States
- Website
- www.tangotx.com
TNGX Metrics
BasicAdvanced
$3.7B
-
-$0.91
1.15
-
Price and volume
Market cap
$3.7B
Beta
1.15
52-week high
$34.39
52-week low
$6.69
Average daily volume
2.4M
Financial strength
Current ratio
50.824
Quick ratio
49.953
Long term debt to equity
0.028
Total debt to equity
0.031
Profitability
EBITDA (TTM)
-134.425
Gross margin (TTM)
-148.37%
Net profit margin (TTM)
-229.92%
Operating margin (TTM)
-253.38%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$390,000
Management effectiveness
Return on assets (TTM)
-12.99%
Return on equity (TTM)
-21.34%
Valuation
Price to revenue (TTM)
54.667
Price to book
3.57
Price to tangible book (TTM)
3.57
Price to free cash flow (TTM)
-20.39
Free cash flow yield (TTM)
-4.90%
Free cash flow per share (TTM)
-1.067
Growth
Revenue change (TTM)
121.48%
Earnings per share change (TTM)
-30.79%
3-year revenue growth (CAGR)
16.89%
3-year earnings per share growth (CAGR)
-8.98%
What the Analysts think about TNGX
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
Analyst projections of the future price of Tango Therapeutics stock.
Bulls say / Bears say
With $1.0 billion in cash and marketable securities as of June 30, 2026, Tango has ample liquidity to fund planned late-stage trials and commercialization activities (Bitget News – Reuters)
The Phase 1/2 combo of vopimetostat with Revolution Medicines’ daraxonrasib shrank tumors in 11 of 12 pancreatic cancer patients (92% ORR) and delivered a 90% six-month progression-free survival rate, supporting rapid advancement into Phase 3 development (Reuters)
The June 22, 2026 appointment of Robert Azelby—former Executive VP and Chief Commercial Officer of Juno Therapeutics—to Tango’s board brings over 30 years of oncology commercialization expertise to support the company’s transition into late-stage development and eventual product launch (Reuters)
Net loss widened to $55.3 million in Q2 2026 from $38.9 million a year earlier, driven by a 13% rise in R&D expenses and a 99% surge in G&A spend, increasing financing pressure on the company (Bitget News – Reuters)
Collaboration revenue fell to zero in Q2 2026 from $3.2 million in Q2 2025, eliminating external partner funding and heightening reliance on the firm's cash runway (SEC 10-Q)
IDEAYA Biosciences initiated Part 2 monotherapy expansion of its PRMT5 inhibitor IDE892 in MTAP-deleted PDAC and NSCLC, intensifying competitive pressure in Tango’s core PRMT5 market (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
TNGX Financial Performance
Revenues and expenses
TNGX Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing TNGX
AllUSDGBPEUR
Fund name | Fund size | $TNGX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.22% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.22% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.11% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.03% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.